RE: Revenues ahead of our expectation4 Sep 2017 09:39
Results from the interim analysis are expected in H1 2018. "Our earlier stage development asset, AP102, remains on track to commence first in-human studies in 2018. "The Company has achieved significant milestones in the first half of 2017 and we remain confident of continuing strong progress over the remainder of 2017 and into 2018."
I like the sound of this!